Our company
Innovating today, shaping tomorrow
An independent in vitro toxicology CRO, specialised in genetic toxicology to predict cancer risk earlier.
-
2017
Founded as a Sanofi / Covance spin-off
-
40+ yrs
Of toxicology expertise in the team
-
1,200 m²
BSL2+ laboratory, Porcheville
-
GLP
ANSM-inspected · COFRAC-certified
About us
Preclinical know-how, built for the next generation of safety testing
Founded in 2017 by Francis Finot and Isabelle Mouche, GenEvolutioN brings together over 40 years of toxicology expertise as a spin-off from Sanofi and Covance's preclinical center.
Hosted in the Seqens lab on Porcheville Scientific Park, we operate a 1,200 m² BSL2+ laboratory designed to keep pace with biological and technological advances.
GLP-compliant, inspected by ANSM for pharmaceuticals, cosmetics and medical devices, and COFRAC-certified for food, chemicals and biocides.
Milestones
-
2017
Founded by Francis Finot and Isabelle Mouche, spin-off from Sanofi / Covance preclinical center.
-
2017
1,200 m² BSL2+ lab in the Seqens building, Porcheville Scientific Park.
-
2023
Certificate of conformity (October).
-
2024
GLP certificates 2024-BPL-023 · Dr Gautier Decock joins as General Manager.
-
2025
CIR research tax credit approval (January).
-
2026
Integrated DMTA partnership with Oxeltis.
People
Meet the specialists behind GenEvolutioN
Leadership team
Catherine Drouet
Quality Assurance Manager
32 years in pharma as Industrial Quality Assurance Officer.
Théo Maconi
Analytical Project Manager
Applied toxicology and client-driven research.
Dr Ange Tchatchouang
In vitro Study Director
Recent PhD, focused on new techniques and innovation.
Advisory board
GenEvolutioN has a biotech advisory board offering expertise that drives innovation, reduces risk and ensures regulatory compliance.
Vision
Become an internationally recognised CRO for in vitro genotoxicity, aimed at predicting cancer risk.
Mission
Contribute to a safer world through innovative laboratory, research and advisory services, creating growth for our people and sustainable value.
Values that define GenEvolutioN
Our DNA of excellence
These principles are woven into the very DNA of GenEvolutioN, inspiring us to lead with purpose and vision.
-
Integrity
Transparency and trust in every action.
-
Confidentiality
Safeguarding the trust of clients and partners.
-
Responsibility
Excellence delivered with accountability.
-
Empathy
Understanding the needs of each stakeholder.
-
Growth
For our team and for our clients alike.
-
Creativity
Innovation to solve complex challenges.
-
Fairness & inclusivity
In every decision we make.
-
Wellness
A positive, supportive environment for all.
Trusted excellence
Certified, and well connected
ANSM
Health authority inspection
CIR
R&D tax credit approval
COFRAC
French accreditation body
Cosmetic Valley
Cluster member
GLP
Good Laboratory Practice
ISO 17025
Laboratory accreditation
JEI
Innovative young enterprise
République Française
French government recognition
AdeBioTech
One Health think tank
ARET
Association pour la Recherche en Toxicologie
ESTIV
European Society of Toxicology In Vitro
SFSTP
Société Française des Sciences et Techniques Pharmaceutiques
SFT
Société Française de Toxicologie
SFTG
Société Française de Toxicologie Génétique
Société Française de Cosmétologie
SOFHYT
Société Française des Hygiénistes du Travail
Université de Franche-Comté
Academic partner
Azurite Life Science
BioHive
Biomnigene
CEHTRA
D2KC
Drug discovery consulting
Delnovat
DiverChim
DRC
Regulatory consulting
Exim-Indis
ExpertTox
Toxicology expertise
Laboratoire Watchfrog
Oxeltis (opens in a new tab)
Medicinal chemistry CRO
Based in Montpellier, specialised in complex organic synthesis, contract synthesis and SFC purification. With GenEvolutioN, Molecular Forecaster and Partex.AI Labs, runs integrated DMTA cycles — from hit identification to lead optimisation, with early safety assessment.
PKDerm
SenzaGen
SEQENS
Xenometrix
Knowledge Center
A hub for insights and expertise
Posters, case studies and webinar replays from our scientific team.
Newsroom
Our latest updates
ICH S10 phototoxicity testing: the 3T3 NRU test and melanin binding
How the GLP 3T3 NRU phototoxicity test and an in vitro melanin binding assay support the ICH S10 photosafety assessment of drug candidates.